Is DARPP-32 a potential therapeutic target?

Authors: Reis, Helton J; Rosa, Daniela VF; Guimarães, Melissa M; Souza, Bruno R; Barros, Alexandre GA; Pimenta, Flávio J; Souza, Renan P; Torres, Karen CL; Romano-Silva, Marco A

Source: Expert Opinion on Therapeutic Targets, Volume 11, Number 12, December 2007 , pp. 1649-1661(13)

Publisher: Informa Healthcare

Buy & download fulltext article:

Price: $99.00 plus tax (Refund Policy)

Abstract:

Signaling pathways play important roles in the coordination and integration of a myriad cellular functions. Because of widespread interest in the dopaminergic pathways, the protein dopamine and cyclic adenosine 3′,5′-monophosphate-regulated phosphoprotein with molecular weight of 32 kDa, known by the acronym DARPP-32, occupies a central role in the biology of dopaminoceptive neurons in the central and peripheral nervous system (PNS). Its involvement has been demonstrated in many neural phenomena, including physiologic and pathologic neuroplasticity to drug effects and cognition. However, DARPP-32 has also been identified in non-neuronal tissues and its level of expression has been associated with the malignant level of some types of cancer, via modulation of cell survival and differentiation. This review considers some of these apparently compartmentalized functions of DARPP-32 and its potential as a therapeutic target.

Keywords: dopamine; mental disorders; neoplasia; phosphatases; phosphoproteins; psychopharmacology; serotonin

Document Type: Research article

DOI: http://dx.doi.org/10.1517/14728222.11.12.1649

Publication date: 2007-12-01

More about this publication?